AG, W., J, F., X, C., B, B. K., T, L., TM, K., . . . SM, T. (2025). Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial. Nature communications, 16(1), 10705. https://doi.org/10.1038/s41467-025-66667-y
Παραπομπή σε μορφή Chicago (17η εκδ.)AG, Waks, et al. "Efficacy, Safety, and Predictive Biomarkers of Neoadjuvant Nab-paclitaxel and Pembrolizumab in Hormone Receptor-positive Breast Cancer: A Randomized Pilot Trial." Nature Communications 16, no. 1 (2025): 10705. https://doi.org/10.1038/s41467-025-66667-y.
Παραπομπή σε μορφή MLA (9th εκδ.)AG, Waks, et al. "Efficacy, Safety, and Predictive Biomarkers of Neoadjuvant Nab-paclitaxel and Pembrolizumab in Hormone Receptor-positive Breast Cancer: A Randomized Pilot Trial." Nature Communications, vol. 16, no. 1, 2025, p. 10705, https://doi.org/10.1038/s41467-025-66667-y.